mAbxience | News

Biosimilars reduce healthcare costs by up to 40% and increase patient accessibility to innovative treatments

05/07/2018

These medicinal products are similar to their counterparts in terms of efficacy, safety and quality, and are backed by comprehensive clinical studies Cancer treatments are some of the ones that benefit the most from this medical innovation, and at a lower price for Health Authorities Treatments with biosimilar medicinal products mean that more patients are […]

5th Castilla y León’s Best Director Awards

04/30/2018

On the occasion of the awards granted by Castilla y León Económica magazine for the fifth year, Luisa Amoedo, director of mAbxience León, has been awarded as Best Export / Internationalization Director. The jury of the 5th Castilla y León’s Best Director Awards is composed of José María Ribot García, General Manager of Instituto para […]

Cancer Chemotherapy and Pharmacology has published comparative data of rituximab biosimilar RTXM83R in lymphoma patients

03/06/2018

The journnal Cancer Chemotherapy and Pharmacology has recently published the randomized, double-blind, phase III and comparative clinical study of pharmacokinetics and pharmacodynamics between RTXM83™ rituximab biosimilar and its reference product in diffuse large B-cell lymphoma patients.  The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax). To demonstrate biosimilarity […]

2nd National Conference on Biosimilars

03/05/2018

mAbxience actively participated in the 2nd National Conference on Biosimilars organised by the Spanish Biosimilar Medicines Association, BioSim. The conference, entitled “Biosimilars: evidence and efficiency”, took place at the Ministry of Health, Social Services and Equality in Madrid on 21st February. Francisco Olivera, Operations Manager at mAbxience León, shared the “Evidence: from R&D to authorisation” […]

INSUD PHARMA is the new name of Chemo Group

11/24/2017

Therefore, our three pharma brands, Chemo, Exeltis and mAbxience, are now grouped together under this name. This new identity is the result of the development and diversification of the company’s pharma activity. Madrid, 24 November 2017–From now on, Chemo Group, the pharmaceutical multinational that is present in over 40 countries, is going to be called […]

mAbxience analyses getting a new plant in Argentina

07/31/2017

The company is part of the multinational CHEMO group, with 40 years’ experience in the pharmaceutical industry and presence in more than 40 countries. The biotechnology company dedicated to the R&D, manufacture and commercialisation of drugs, mainly biosimilars medicines, already has an R&D centre in Spain, together with a monoclonal antibody production plant in Munro, […]

mAbxience at EACPT 2017

06/27/2017

Within the framework of the 13th Congress of the European Association of Clinical and Therapeutic Pharmacology (EACPT), held in Prague between 24th and 27th June, Dr Francisco Javier Fernández, medical advisor at mAbxience, presented the results of the population pharmacokinetic modelling the Rituximab (RTXM83) clinical study. It is an international clinical study conducted in 58 […]

BioSim visits mAbxience biosimilar production plant

04/11/2017

On April 5th we received in our plant in León the visit of a wide representation of the members of BioSim and the team of the association, headed by Joaquín Rodrigo, President, and Regina Múzquiz, Managing Director. Emmanuelle Lepine, General Manager of mAbxience, Naouel Zouaghi, Marketing and Public Affairs director and Luisa Amoedo, site director, […]

mAbxience, European success accelerating global growth

02/13/2017

mAbxience is proud to announce that it has recently received the GMP Certification from the Spanish Agency of Medicines and Health Products (AEMPS), one of the strictest and highest regarded regulatory agencies in the world. This is another success towards realization of our international growth plan.  With this certification mAbxience now has the green light […]

mAbxience, present in the World Biosimilar Congress Europe 2016

11/23/2016

Last week mAbxience took part in one of the landmark events of the biosimilar sector, the World Biosimilar Congress Europe 2016, held on 14th and 15th November in Basel, Switzerland. As every year, the most important companies of the industry attended this event, as well as representatives of official organisms of the sector and universities. […]